DEF 14A

Company

Kalaris Therapeutics, Inc.

Filed

April 23, 2024

Period of Report

June 6, 2024

Accession Number

0001193125-24-106976

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →